NCT02202655

Brief Summary

The purpose of this study is to investigate the changes of lymphocyte subsets in chemotherapy course of patients with non-small cell lung cancer

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started May 2014

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2014

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

June 24, 2014

Completed
1 month until next milestone

First Posted

Study publicly available on registry

July 29, 2014

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2015

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2015

Completed
Last Updated

July 29, 2014

Status Verified

July 1, 2014

Enrollment Period

1.1 years

First QC Date

June 24, 2014

Last Update Submit

July 28, 2014

Conditions

Keywords

non- small cell lung cancer;lymphocyte subsets

Outcome Measures

Primary Outcomes (1)

  • the changes of patients' lymphocyte subsets in chemotherapy courses.

    up to cycle 4 day 9

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients with non-small cell lung cancer who accept chemotherapy for the first time are acceptable.

You may qualify if:

  • Each Period Non-small Cell Lung Cancer, Which Was Confirmed by Histopathology. patients has only lung cancer .
  • Functional Status Score (PS) ≧ 70.
  • The first time for chemotherapy .
  • A Written Informed Consent.

You may not qualify if:

  • Merging other tumors.
  • HAve autoimmune diseases.
  • AIDS

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

WangQian

Beijing, Beijing Municipality, 100020, China

RECRUITING

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • yingmin ma

    Vice President of the Beijing chaoyang hospital

    STUDY DIRECTOR

Central Study Contacts

qian wang, master

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Vice President of the Beijing chaoyang hospital

Study Record Dates

First Submitted

June 24, 2014

First Posted

July 29, 2014

Study Start

May 1, 2014

Primary Completion

June 1, 2015

Study Completion

September 1, 2015

Last Updated

July 29, 2014

Record last verified: 2014-07

Locations